Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
12:46pm, Tuesday, 05'th Jul 2022
The FDA appears to be reconsidering its position regarding the biotech's ALS drug candidate.
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug
12:05pm, Tuesday, 05'th Jul 2022
A new wrinkle in the story of Amylyx Pharmaceuticals' ongoing battle against ALS bodes well for patients, and for AMLX stock holders. The post Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion
Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
09:34am, Monday, 04'th Jul 2022
The Canadian approval has significantly increased the probability of a positive PDUFA despite negative AdCom. Phase 2 CENTAUR trial showed a slowing of functional decline and improved survival in ALS,
4 Top Biotech Stocks To Watch Today
03:00pm, Friday, 17'th Jun 2022
As the industry continues to make new discoveries, could biotech stocks be in focus?
Here's How Citi Views Amylyx Pharma
03:11pm, Tuesday, 14'th Jun 2022
Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrop
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
11:39am, Friday, 03'rd Jun 2022
Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA). The post Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today
09:47am, Friday, 03'rd Jun 2022
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035. Amylyx
Amylyx says FDA decision date for ALS therapy is now in September; shares jump
08:20am, Friday, 03'rd Jun 2022
Shares of Amylyx Pharmaceuticals Inc. Inc. AMLX, +14.27% soared 21.6% in premarket trading on Friday after the company said U.S. regulators extended the review time for its experimental amyotrophic la
Amylyx's ALS Drug Application Hangs In The Balance
11:34pm, Thursday, 31'st Mar 2022
On March 30, FDA's advisory committee voted 6 No to 4 Yes, to the question if AMLX's single phase 2 trial data established its effectiveness in treating ALS.
Could Amylyx Pharmaceuticals Have a Blockbuster ALS Treatment?
05:45am, Tuesday, 29'th Mar 2022
The FDA's currently looking at an application for the company's lead candidate.
Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug
03:16pm, Monday, 28'th Mar 2022
The FDA released its briefing documents for the advisory committee to discuss Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) sodium phenylbutyrate/taurursodiol (AMX0035) powder for amyotrophic latera
Here's Why Amylyx Pharmaceuticals Stock Is Getting Hammered on Monday
12:04pm, Monday, 28'th Mar 2022
It seems the FDA isn't going to approve the company's ALS drug before an ongoing phase 3 trial produces evidence of efficacy.
7 Biotech Stocks With Key Catalysts in March
06:24am, Wednesday, 09'th Mar 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest
Andreas Halvorsen Gets in on Amylyx Pharmaceuticals' IPO
12:59pm, Tuesday, 25'th Jan 2022
Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.
U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week
11:36pm, Saturday, 08'th Jan 2022
The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Four SPACs went public led by Sagansky and Sloan's Screaming Eagle Acquisition, whic
